Subcutaneous low-molecular-weight heparin for treatment of Trousseau's syndrome.
We report the case of a 76-year-old man with recurrent thromboses despite oral anticoagulation with phenprocoumon and low-grade chronic disseminated intravascular coagulation. Workup revealed a bronchial carcinoma (NSCCL) with hilar and mediastinal lymph node metastases. The clinical condition was consistent with Trousseau's syndrome. Based on reports in the literature, the therapy was changed to intravenous unfractionated heparin (UFH), which was effective in controlling the thrombotic coagulopathy. For practical reasons, despite a lack of evidence of its effectiveness in Trousseau's syndrome, therapy with UFH was changed to subcutaneous low-molecular-weight heparin (LMWH, nadroparine) in therapeutic doses of 100 IU/ kg body wt. 12 hourly. On an outpatient basis, five chemotherapy cycles were administered, and after metastases of the brain had been detected radiotherapy was initiated. Following 7.5 months of progressive neoplastic disease the patient died. He had remained free of thromboembolic complications under continued LMWH therapy during the last 6.5 months of his life. LMWH might be a convenient alternative to the established therapy with UFH in Trousseau's syndrome.
Züger
M
M
Central Hematology Laboratory, Inselspital, University Hospital of Bern, Switzerland.
Demarmels Biasiutti
F
F
Wuillemin
W A
WA
Furlan
M
M
Lämmle
B
B
D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D002283:Carcinoma, Bronchogenic / Q000150:complications; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications; D006801:Humans; D007279:Injections, Subcutaneous; D008175:Lung Neoplasms / Q000150:complications; D008297:Male; D017762:Nadroparin / Q000008:administration & dosage / Q000627:therapeutic use*; D010257:Paraneoplastic Syndromes / Q000150:complications / Q000188:drug therapy*; D013924:Thrombophlebitis / Q000150:complications / Q000188:drug therapy*
D000925:Anticoagulants; D017762:Nadroparin